Invasive Pneumococcal Disease in New Zealand, 2010

More documents

Recommendations

Info

Appendix 12. Trends in resistance to non-β-lactam antibiotics, among pneumococci from invasive disease, 2001-2010 1YearNumberofisolatesChloramphenicol Clindamycin 2 Co-trimoxazole Erythromycin Tetracycline%S 3 %R 3 %S %I 3 %R 4 %S %I %R %S %I %R %S %I %R2001 537 98.7 1.3 62.8 6.0 31.3 94.2 0.4 5.4 94.8 0.2 5.02002 490 97.6 2.5 62.5 1.4 36.1 90.6 0.4 9.0 93.1 0.0 6.92003 523 96.6 3.4 64.4 1.7 33.8 90.1 0.6 9.4 91.0 0.4 8.62004 545 97.3 2.8 61.1 0.2 38.7 91.4 0.2 8.4 91.9 0.2 7.92005 492 96.8 3.3 67.3 0.6 32.1 87.8 0.0 12.2 90.9 0.6 8.52006 522 98.5 1.5 65.7 1.5 32.8 88.7 0.2 11.1 92.5 0.4 7.12007 555 97.7 2.3 93.7 0.0 6.3 63.2 1.8 35.0 86.0 0.4 13.7 90.8 0.7 8.52008 630 97.6 2.4 94.6 0.0 5.4 67.6 2.2 30.2 87.8 0.3 11.9 91.9 0.5 7.62009 665 98.8 1.2 95.3 0.2 4.5 72.6 2.1 25.3 90.2 0.2 9.6 92.5 0.3 7.22010 514 98.1 2.0 94.7 0.0 5.3 73.5 2.1 24.3 91.1 0.0 9.0 91.6 0.8 7.61 All isolates susceptible to vancomycin. Moxifloxacin susceptibility tested since 2005, with no resistance identified and a maximum of one isolate per annum with intermediateresistance. Rifampicin susceptibility tested in 2010 only, with no resistance identified.2 Clindamycin susceptibility tested since 2007.3 S, susceptible; I, intermediate; R, resistant.4 Includes isolates with inducible clindamycin resistance.Invasive pneumococcal disease 38 September 2011in NZ, 2010
Appendix 13. Penicillin and cefotaxime resistance among isolates from invasivepneumococcal disease by region and district health board (DHB), 2010Region and DHBNumber ofisolatesPenicillin% resistant 1MIC 0.12 mg/LCefotaxime% intermediate 1MIC 1 mg/L% resistant 1MIC 2 mg/LNorthland region 214 19.2 6.1 1.9Northland 17 11.8 5.9 0.0Waitemata 56 28.6 8.9 1.8Auckland 43 20.9 2.3 0.0Counties Manukau 98 14.3 6.1 3.1Midland region 107 15.9 3.7 2.8Waikato 47 21.3 8.5 4.3Lakes 18 5.6 0.0 0.0Bay of Plenty 31 12.9 0.0 3.2Tairawhiti 1 0.0 0.0 0.0Taranaki 10 20.0 0.0 0.0Central region 102 17.7 5.9 2.0Hawke's Bay 22 13.6 9.1 0.0Whanganui 9 33.3 0.0 0.0MidCentral 18 22.2 5.6 5.6Hutt 21 14.3 9.5 0.0Capital and Coast 23 21.7 4.4 4.4Wairarapa 5 0.0 0.0 0.0Nelson Marlborough 4 0.0 0.0 0.0Southern region 91 18.7 9.9 1.1West Coast 1 0.0 0.0 0.0Canterbury 40 22.5 7.5 2.5South Canterbury 3 33.3 0.0 0.0Southern 7 14.9 12.8 0.0New Zealand total 514 18.1 6.2 2.01 Meningitis interpretations; no intermediate category for penicillin.Invasive pneumococcal disease 39 September 2011in NZ, 2010
Page 1 and 2: INVASIVE PNEUMOCOCCAL DISEASEIN NEW
Page 3 and 4: DISCLAIMERThis report or document (
Page 5 and 6: CONTENTSSUMMARY ...................
Page 7 and 8: SUMMARYA 4-dose schedule of the 7-v
Page 9 and 10: 1. INTRODUCTIONPrior to 2009, the n
Page 11 and 12: Data analyses were performed with S
Page 13 and 14: 3. RESULTSIn 2010, 535 IPD cases we
Page 15 and 16: The all-age rate of IPD in 2010 (12
Page 17: 3.4 Disease incidence by ethnicityT
Page 20 and 21: 3.7 Risk factors among IPD casesThe
Page 23 and 24: 3.10 Serotype distributionTable 9.
Page 25 and 26: Rate per 100 000The rate of disease
Page 27 and 28: 3.11 Antimicrobial susceptibilityTa
Page 29 and 30: Percent of penicillin-resistant iso
Page 31 and 32: type most frequently reported to ha
Page 33 and 34: REFERENCES1 Green MJ, Cawley PFM. I
Page 35 and 36: Appendix 1. Laboratory criteria upo
Page 37 and 38: Appendix 3. Rates of invasive pneum
Page 39 and 40: Appendix 5.2010Risk factors among i
Page 41 and 42: Appendix 7. Serotypes among invasiv
Page 43 and 44: Appendix 9. Serotype 1 invasive pne
Page 45: Appendix 11. Trends in penicillin r
Page 49: Appendix 15. Trends in penicillin r

Invasive Pneumococcal Disease in New Zealand, 2010

Create successful ePaper yourself

Delete template?

Save as template?